Drug intelligence / Profile preview

IBL-100

Development stage: Preclinical
Lead developer: Inflection Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**IBL-100** is a selective **pan-PIM kinase inhibitor** (targeting PIM1, PIM2, and PIM3) developed by **Inflection Biosciences Ltd**, licensed from the **Spanish National Cancer Research Centre (CNIO)**. It is a **small molecule** in preclinical development primarily for **solid tumors** such as **lung cancer** and **AML**, with emerging exploration in **autoimmune diseases** via the related **IBL-100s** series. Preclinical data demonstrate proof-of-concept efficacy, and it is part of a broader pipeline including partnered assets like **AUM302**.[2][10][11]

Targets

PIM2 (Proto-oncogene serine/threonine-protein kinase Pim2)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)PIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)

Beyond the preview

Go deeper on IBL-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBL-100.

Explore the full profile